Patents Assigned to Teva Women's Health, Inc.
-
Patent number: 9220692Abstract: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.Type: GrantFiled: May 5, 2011Date of Patent: December 29, 2015Assignee: TEVA WOMEN'S HEALTH, INC.Inventors: Charles E. DiLiberti, Anu Mahashabde
-
Patent number: 8980304Abstract: The present invention relates to annular intravaginal devices comprising an aperture, methods of making, and uses thereof. The annular devices comprise an aperture extending into the device, the aperture having: (a) an interior diameter, and (b) an exterior entry diameter, wherein the exterior entry diameter of the aperture is less than the interior diameter of the aperture.Type: GrantFiled: August 18, 2011Date of Patent: March 17, 2015Assignee: Teva Women's Health, Inc.Inventor: Jiaxiang Tsao
-
Patent number: 8680084Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: GrantFiled: August 30, 2012Date of Patent: March 25, 2014Assignee: Teva Women's Health, Inc.Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
-
Patent number: 8663681Abstract: The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.Type: GrantFiled: May 26, 2006Date of Patent: March 4, 2014Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Charles E. Diliberti, Chandra Vattikonda, Sudhir R. Gorukanti, Sanjeev K. Gupta
-
Publication number: 20140030311Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: TEVA WOMEN'S HEALTH, INC.Inventors: Salah U. AHMED, Jiaxiang TSAO, Anu MAHASHABDE, Diane D. HARRISON
-
Patent number: 8580293Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.Type: GrantFiled: February 3, 2009Date of Patent: November 12, 2013Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
-
Publication number: 20130269706Abstract: The present invention relates to annular intravaginal devices comprising an aperture, methods of making, and uses thereof. The annular devices comprise an aperture extending into the device, the aperture having: (a) an interior diameter, and (b) an exterior entry diameter, wherein the exterior entry diameter of the aperture is less than the interior diameter of the aperture.Type: ApplicationFiled: August 18, 2011Publication date: October 17, 2013Applicant: TEVA WOMEN'S HEALTH, INC.Inventor: Jiaxiang Tsao
-
Patent number: 8338396Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: GrantFiled: May 24, 2010Date of Patent: December 25, 2012Assignee: Teva Women's Health, Inc.Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
-
Patent number: 8323679Abstract: The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same.Type: GrantFiled: January 5, 2011Date of Patent: December 4, 2012Assignee: TEVA Women's Health, Inc.Inventors: Salah U. Ahmed, Tahseen A. Chowdhury, Yi Luo
-
Patent number: 8288342Abstract: The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate.Type: GrantFiled: October 12, 2009Date of Patent: October 16, 2012Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Sundeep Sethia, Kathleen Reape, Howard Hait, Carole S. Ben-Maimon
-
Publication number: 20120252767Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: ApplicationFiled: June 8, 2012Publication date: October 4, 2012Applicant: Teva Women's Health, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
-
Patent number: 8247393Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.Type: GrantFiled: August 17, 2007Date of Patent: August 21, 2012Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Madhu Sudhan Shaik, Sanjeev K. Gupta
-
Publication number: 20120207798Abstract: The present invention relates to a method of attaching a handle to a solid oral dosage form by use of high frequency mechanical vibrations. The present invention also relates to a method of attaching a handle to a solid oral dosage form, the method comprising: (a) placing a handle in contact with a solid oral dosage form, wherein an area of contact between the handle and the solid oral dosage form forms a joint interface; (b) applying high frequency mechanical vibrations to the joint interface until the solid oral dosage form at the joint interface reaches a molten state; and (c) cooling the joint interface in a molten state to allow solidification, thereby attaching the handle to the solid oral dosage form.Type: ApplicationFiled: April 26, 2012Publication date: August 16, 2012Applicant: Teva Women's Health, Inc.Inventors: Tahseen A. CHOWDHURY, Edward J. GABRIELSKI, Christopher H. BAKER
-
Patent number: 8217024Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.Type: GrantFiled: December 27, 2006Date of Patent: July 10, 2012Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Madhu Sudhan Shaik, Sanjeev K. Gupta
-
Patent number: 8202534Abstract: The present invention relates to a method of attaching a handle to a solid oral dosage form by use of high frequency mechanical vibrations. The present invention also relates to a method of attaching a handle to a solid oral dosage form, the method comprising: (a) placing a handle in contact with a solid oral dosage form, wherein an area of contact between the handle and the solid oral dosage form forms a joint interface; (b) applying high frequency mechanical vibrations to the joint interface until the solid oral dosage form at the joint interface reaches a molten state; and (c) cooling the joint interface in a molten state to allow solidification, thereby attaching the handle to the solid oral dosage form.Type: GrantFiled: June 5, 2006Date of Patent: June 19, 2012Assignee: Teva Women's Health, Inc.Inventors: Tahseen A. Chowdhury, Edward J. Gabrielski, Christopher H. Baker
-
Patent number: 8148560Abstract: The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about 1:50 to about 1:800, and wherein the vaginal tablets do not substantially change the pH of a vaginal tract.Type: GrantFiled: September 25, 2006Date of Patent: April 3, 2012Assignee: Teva Women's Health, Inc.Inventors: Salah U. Ahmed, Raj R. Mahajan
-
Publication number: 20110124611Abstract: The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.Type: ApplicationFiled: October 26, 2010Publication date: May 26, 2011Applicant: TEVA WOMEN'S HEALTH, INC.Inventors: ROBERT G. BELL, CAROLE S. BEN-MAIMON, BEATA ISKOLD, LANCE J. BRONNENKANT, HOWARD HAIT, KATHLEEN Z. REAPE
-
Patent number: 7908729Abstract: A method for attaching a handle to a tablet to form a lollipop utilizes a specific work holder. The work holder has a tooling pallet with a plurality of openings going from a top surface to a bottom surface. A bullet and a spring are located in each opening and held in place by a plate that slides through a groove in the bottom surface of the tooling pallet to block the openings in the bottom surface. Each spring is positioned between a bullet and the plate. A tablet is placed in a cavity of each bullet and a handle is placed in contact with each tablet. High frequency mechanical vibrations, such as ultrasonic vibrations, are applied to a joint interface between each tablet and bullet until the joint interface reaches a molten state. The joint interfaces are then allowed to cool, thereby attaching a handle to each tablet and forming a lollipop.Type: GrantFiled: November 3, 2006Date of Patent: March 22, 2011Assignee: Teva Women's Health, Inc.Inventors: Tahseen A. Chowdhury, Edward J. Gabrielski, Christopher H. Baker
-
Patent number: 7910126Abstract: The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same.Type: GrantFiled: March 20, 2007Date of Patent: March 22, 2011Assignee: TEVA Women's Health, Inc.Inventors: Salah U. Ahmed, Tahseen A. Chowdhury, Yi Luo
-
Patent number: 7858605Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: GrantFiled: December 6, 2007Date of Patent: December 28, 2010Assignee: Teva Women's Health, Inc.Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold